Evidence map›Paper›PMID 30072615›Full record

ReviewInternational journal of molecular sciences2018

STAT3 in Skeletal Muscle Function and Disorders.

Eleonora Guadagnin, Davi Mázala, Yi-Wen Chen

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Decreased IL-17-producing TThe journal of allergy and clinical immunology. Global · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Eleonora GuadagninDepartment of Orthopeadic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. eguadagnin@bwh.harvard.edu.
Davi MázalaCenter for Genetic Medicine Research, Children's National Health System, Washington, DC 20010, USA. dmazala@childrensnational.org.
Yi-Wen ChenCenter for Genetic Medicine Research, Children's National Health System, Washington, DC 20010, USA. ychen@childrensnational.org.
Brigham and Women's Hospital · USChildren's National · USGeorge Washington University · US

Funding

Genetics and Genomics of Muscle Postdoctoral Training ProgramT32AR056993 · NIAMS · CHILDREN'S RESEARCH INSTITUTE · PI JAISWAL, JYOTI K, PARTRIDGE, TERENCE A · 2010 to 2019
$2.2M
6 · The paper itself

Abstract

Signal transducer and activator of transcription 3 (STAT3) signaling plays critical roles in regulating skeletal muscle mass, repair, and diseases. In this review, we discuss the upstream activators of STAT3 in skeletal muscles, with a focus on interleukin 6 (IL6) and transforming growth factor beta 1 (TGF-β1). We will also discuss the double-edged effect of STAT3 activation in the muscles, including the role of STAT3 signaling in muscle hypertrophy induced by exercise training or muscle wasting in cachectic diseases and muscular dystrophies. STAT3 is a critical regulator of satellite cell self-renewal after muscle injury. STAT3 knock out affects satellite cell myogenic progression by impairing proliferation and inducing premature differentiation. Recent studies in STAT3 signaling demonstrated its direct role in controlling myogenic capacity of myoblasts and satellite cells, as well as the potential benefit in using STAT3 inhibitors to treat muscle diseases. However, prolonged STAT3 activation in muscles has been shown to be responsible for muscle wasting by activating protein degradation pathways. It is important to balance the extent of STAT3 activation and the duration and location (cell types) of the STAT3 signaling when developing therapeutic interventions. STAT3 signaling in other tissues and organs that can directly or indirectly affects skeletal muscle health are also discussed.

Indexed as

AnimalsHumansInflammationInterleukin-6Muscle, SkeletalMuscular DiseasesSatellite Cells, Skeletal MuscleSignal TransductionSTAT3 Transcription FactorTransforming Growth Factor beta1Interleukin-6STAT3 Transcription FactorTransforming Growth Factor beta1atrophyhypertrophyIL6musclesatellite cellsSTAT3TGF

Identifiers

PMID30072615
PMCPMC6121875
OpenAlexW2886047510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.